These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22611406)

  • 1. Development of an IgG4-RD Responder Index.
    Carruthers MN; Stone JH; Deshpande V; Khosroshahi A
    Int J Rheumatol; 2012; 2012():259408. PubMed ID: 22611406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index.
    Wallace ZS; Khosroshahi A; Carruthers MD; Perugino CA; Choi H; Campochiaro C; Culver EL; Cortazar F; Della-Torre E; Ebbo M; Fernandes A; Frulloni L; Hart PA; Karadag O; Kawa S; Kawano M; Kim MH; Lanzillotta M; Matsui S; Okazaki K; Ryu JH; Saeki T; Schleinitz N; Tanasa P; Umehara H; Webster G; Zhang W; Stone JH
    Arthritis Care Res (Hoboken); 2018 Nov; 70(11):1671-1678. PubMed ID: 29457382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).
    Stone JH; Hoffman GS; Merkel PA; Min YI; Uhlfelder ML; Hellmann DB; Specks U; Allen NB; Davis JC; Spiera RF; Calabrese LH; Wigley FM; Maiden N; Valente RM; Niles JL; Fye KH; McCune JW; St Clair EW; Luqmani RA;
    Arthritis Rheum; 2001 Apr; 44(4):912-20. PubMed ID: 11318006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for IgG4-related disease: a prospective, open-label trial.
    Carruthers MN; Topazian MD; Khosroshahi A; Witzig TE; Wallace ZS; Hart PA; Deshpande V; Smyrk TC; Chari S; Stone JH
    Ann Rheum Dis; 2015 Jun; 74(6):1171-7. PubMed ID: 25667206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index.
    Fernández-Codina A; Pinilla B; Pinal-Fernández I; López C; Fraile-Rodríguez G; Fonseca-Aizpuru E; Carballo I; Brito-Zerón P; Feijóo-Massó C; López-Dupla M; Cid MC; Martínez-Valle F; ; ;
    Joint Bone Spine; 2018 Dec; 85(6):721-726. PubMed ID: 29452298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease.
    Berti A; Della-Torre E; Gallivanone F; Canevari C; Milani R; Lanzillotta M; Campochiaro C; Ramirez GA; Bozzalla Cassione E; Bozzolo E; Pedica F; Castiglioni I; Arcidiacono PG; Balzano G; Falconi M; Gianolli L; Dagna L
    Rheumatology (Oxford); 2017 Dec; 56(12):2084-2092. PubMed ID: 28977663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients.
    Khosroshahi A; Carruthers MN; Deshpande V; Unizony S; Bloch DB; Stone JH
    Medicine (Baltimore); 2012 Jan; 91(1):57-66. PubMed ID: 22210556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients.
    Wallace ZS; Deshpande V; Mattoo H; Mahajan VS; Kulikova M; Pillai S; Stone JH
    Arthritis Rheumatol; 2015 Sep; 67(9):2466-75. PubMed ID: 25988916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major salivary gland enlargement in IgG4-related disease is associated with multiorgan involvement and higher basal disease activity.
    Martín-Nares E; Ángeles-Ángeles A; Hernandez-Molina G
    Mod Rheumatol; 2020 Jan; 30(1):172-177. PubMed ID: 30676828
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of serum levels of fibrosis-related biomarkers with disease activity in patients with IgG4-related disease.
    Kawashiri SY; Origuchi T; Umeda M; Nishino A; Shimizu T; Fukui S; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Maeda T; Kawano M; Yamamoto M; Izumi Y; Kawakami A
    Arthritis Res Ther; 2018 Dec; 20(1):277. PubMed ID: 30547825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients.
    Campochiaro C; Ramirez GA; Bozzolo EP; Lanzillotta M; Berti A; Baldissera E; Dagna L; Praderio L; Scotti R; Tresoldi M; Roveri L; Mariani A; Balzano G; Castoldi R; Doglioni C; Sabbadini MG; Della-Torre E
    Scand J Rheumatol; 2016; 45(2):135-45. PubMed ID: 26398142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab.
    Backhus J; Neumann C; Perkhofer L; Schulte LA; Mayer B; Seufferlein T; Müller M; Kleger A
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33807051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying clinical subgroups in IgG4-related disease patients using cluster analysis and IgG4-RD composite score.
    Li J; Peng Y; Zhang Y; Zhang P; Liu Z; Lu H; Peng L; Zhu L; Xue H; Zhao Y; Zeng X; Fei Y; Zhang W
    Arthritis Res Ther; 2020 Jan; 22(1):7. PubMed ID: 31924265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features and outcomes in a cohort of patients with immunoglobulin G4-related disease at a university hospital in Spain.
    Quero M; Draibe J; Solanich X; Rama I; Gomà M; Martínez-Valenzuela L; Fulladosa X; Cruzado JM; Torras J
    Clin Kidney J; 2019 Dec; 12(6):829-835. PubMed ID: 31807295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary artery wall contrast enhancement imaging impact on disease activity assessment in IgG4-RD: a direct marker of coronary involvement.
    Du Y; Ding S; Li C; Bai Y; Wang X; Li D; Xie Y; Fan G; Wu LM; Wang G
    J Cardiovasc Magn Reson; 2024 May; 26(2):101047. PubMed ID: 38825155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review.
    Wang Y; Li K; Gao D; Luo G; Zhao Y; Wang X; Zhang J; Jin J; Zhao Z; Yang C; Zhu J; Zhang J; Huang F
    Intern Med J; 2017 Jun; 47(6):680-689. PubMed ID: 28321964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do ANCA-associated vasculitides and IgG4-related disease really overlap or not?
    Erden A; Bolek EC; Yardimci KG; Kilic L; Bilgen SA; Karadag O
    Int J Rheum Dis; 2019 Oct; 22(10):1926-1932. PubMed ID: 31571413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous presentation of granulomatosis with polyangiitis (GPA) and immunoglobulin G4-related disease (IgG4-RD). Leaving an open question: widening the spectrum of a single disease or real overlap?
    Boncoraglio MT; Prieto-González S; Fernandes-Serodio J; Corral-Molina JM; Solé M; Hernández-Rodríguez J
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):108-112. PubMed ID: 33269656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of second-line steroid sparing immunosuppressants like mycophenolate mofetil improves outcome of Immunoglobulin G4-related disease (IgG4-RD): a series from a tertiary care teaching hospital in South India.
    Gupta N; Mathew J; Mohan H; Chowdhury SD; Kurien RT; Christopher DJ; Thangakunam B; Alexander M; Sivadasan A; Tamilarasi V; Valson AT; Gowri M; Kabeerdoss J; Danda D
    Rheumatol Int; 2018 Feb; 38(2):203-209. PubMed ID: 28550399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgG4-positive plasma cells in granulomatosis with polyangiitis (Wegener's): a clinicopathologic and immunohistochemical study on 43 granulomatosis with polyangiitis and 20 control cases.
    Chang SY; Keogh KA; Lewis JE; Ryu JH; Cornell LD; Garrity JA; Yi ES
    Hum Pathol; 2013 Nov; 44(11):2432-7. PubMed ID: 23993777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.